cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.6084/m9.figshare.23666253
title: Supplementary Material for: Conversion From Intermittent Hemodialysis to Peritoneal dialysis in metastatic Catheter-Related Blood Stream Infection

description: Of all complications from Central Venous Catheters (CVC) in End-Stage Renal Disease [ESRD] patients, Catheter-Related Blood Stream Infection [CRBSI] is one of the most devastating consequences. The option of catheter salvage is not an effective measure with metastatic infections. However, in patients with severe vasculopathy and/or near end-stage vascular disease, preservation of the venous access should be given utmost importance as the luxury of utilizing another vascular site is markedly limited. Providing adequate renal replacement therapy in this group of patients can be remarkably challenging for Nephrologists. We are presenting an ESRD patient with advanced vascular disease who developed metastatic catheter-related bloodstream infection (CRBSI) with worsening uremia who was successfully converted from Intermittent hemodialysis [IHD] to Peritoneal dialysis [P.D]. Our rationale was to minimize repeated intravascular procedures coupled with the presence of another intravascular device. This has led to a complete resolution of persistent bacteremia, with a steady improvement in the uremic state. Conversion from IHD to PD for persistent bacteremia with metastatic complications was seldom addressed in literature. In the absence of a significant contraindication to PD, it can be considered as a valid alternative possibility in order to interrupt this viscous cycle especially in vasculopathic patients.
DOI: 10.17617/4.db
title: Vinylene-Linked 2D Conjugated Covalent Organic Frameworks by Wittig Reactions

description: Liu, Y., Fu, S., Pastoetter, D. L., Khan, A. H., Zhang, Y., Dianat, A., et al. (2022). Vinylene-Linked 2D Conjugated Covalent Organic Frameworks by Wittig Reactions. Angewandte Chemie International Edition, 61(49): e202209762. doi:10.1002/anie.202209762.
DOI: 10.6084/m9.figshare.23702220
title: Supplementary Material for: A case of rapidly progressive diabetic nephropathy induced by osimertinib

description: The number of patients with diabetic nephropathy is increasing worldwide and it is important to understand the underlying pathological mechanisms of the disease. In early-stage diabetic nephropathy, the hyperglycemic environment leads to vascular endothelial cell damage, resulting in overexpression of vascular endothelial growth factor (VEGF) in podocytes and renal pathology of glomerular hypertrophy, glomerular basement membrane thickening, and mesangial hyperplasia. In diabetic nephropathy, renal thrombotic microangiopathy (TMA) develops and the nephropathy progressively worsens in some cases of severe glomerular podocyte damage. Further, receptor tyrosine kinase inhibitors (RTKIs) may suppress VEGF secretion via VEGF receptor-2 tyrosine kinase inhibition in podocytes, which results in renal TMA and rapid deterioration of diabetic nephropathy. Osimertinib, a third-generation irreversible epidermal growth factor receptor (EGFR)-TKI, is approved as a first-line treatment agent for metastatic or locally advanced EGFR mutation-positive non-small cell lung cancer. We encountered a case of a patient with diabetic nephropathy with lung adenocarcinoma treated with osimertinib, whose condition deteriorated from early nephropathy to end-stage renal disease in approximately 4 months. The patient had early diabetic nephropathy, but the use of a RTKI suppressed VEGF expression in podocytes, resulting in the induction of renal TMA and the development of rapidly progressive diabetic nephropathy.
DOI: 10.6084/m9.figshare.23702220.v1
title: Supplementary Material for: A case of rapidly progressive diabetic nephropathy induced by osimertinib

description: The number of patients with diabetic nephropathy is increasing worldwide and it is important to understand the underlying pathological mechanisms of the disease. In early-stage diabetic nephropathy, the hyperglycemic environment leads to vascular endothelial cell damage, resulting in overexpression of vascular endothelial growth factor (VEGF) in podocytes and renal pathology of glomerular hypertrophy, glomerular basement membrane thickening, and mesangial hyperplasia. In diabetic nephropathy, renal thrombotic microangiopathy (TMA) develops and the nephropathy progressively worsens in some cases of severe glomerular podocyte damage. Further, receptor tyrosine kinase inhibitors (RTKIs) may suppress VEGF secretion via VEGF receptor-2 tyrosine kinase inhibition in podocytes, which results in renal TMA and rapid deterioration of diabetic nephropathy. Osimertinib, a third-generation irreversible epidermal growth factor receptor (EGFR)-TKI, is approved as a first-line treatment agent for metastatic or locally advanced EGFR mutation-positive non-small cell lung cancer. We encountered a case of a patient with diabetic nephropathy with lung adenocarcinoma treated with osimertinib, whose condition deteriorated from early nephropathy to end-stage renal disease in approximately 4 months. The patient had early diabetic nephropathy, but the use of a RTKI suppressed VEGF expression in podocytes, resulting in the induction of renal TMA and the development of rapidly progressive diabetic nephropathy.
DOI: 10.6084/m9.figshare.23551422
title: Supplementary Material for: Cross-Cultural Disparities in Psychosocial Research with Individuals with Classical Congenital Adrenal Hyperplasia: A Scoping Review

description: Objective There are increased calls to address psychosocial needs among individuals with classical Congenital Adrenal Hyperplasia (CAH). However, cross-cultural disparities exist in treatment practices and psychosocial outcomes that impact the generalizability of evidence-based recommendations. To date, this disparity has not been quantified. The present scoping review uses a dual approach to contrast rates of CAH diagnosis to CAH psychosocial research rates across countries. Methods Six electronic database searches were conducted for: (1) CAH incidence/birth/prevalence rates, and (2) psychosocial research with affected individuals and their families. Two authors reviewed each abstract for inclusion criteria. Results Sixty-eight and 93 full-text articles, respectively, were evaluated for incidence and country. The countries/regions with the highest reported CAH rates are Thailand, Ghana, and India. Those with the greatest portion of psychosocial publications are United States, Germany, and United Kingdom. Discussion A discrepancy exists between those countries with the highest CAH rates and those publishing psychosocial research. Specifically, increased rates of CAH are seen in non-Western countries/regions, whereas most psychosocial research arises out of Western Europe and the US. Due to cultural differences between these regions, increased global collaboration is needed to both inform psychosocial research and translate findings in ways that are representative worldwide.
DOI: 10.6084/m9.figshare.23551422.v1
title: Supplementary Material for: Cross-Cultural Disparities in Psychosocial Research with Individuals with Classical Congenital Adrenal Hyperplasia: A Scoping Review

description: Objective There are increased calls to address psychosocial needs among individuals with classical Congenital Adrenal Hyperplasia (CAH). However, cross-cultural disparities exist in treatment practices and psychosocial outcomes that impact the generalizability of evidence-based recommendations. To date, this disparity has not been quantified. The present scoping review uses a dual approach to contrast rates of CAH diagnosis to CAH psychosocial research rates across countries. Methods Six electronic database searches were conducted for: (1) CAH incidence/birth/prevalence rates, and (2) psychosocial research with affected individuals and their families. Two authors reviewed each abstract for inclusion criteria. Results Sixty-eight and 93 full-text articles, respectively, were evaluated for incidence and country. The countries/regions with the highest reported CAH rates are Thailand, Ghana, and India. Those with the greatest portion of psychosocial publications are United States, Germany, and United Kingdom. Discussion A discrepancy exists between those countries with the highest CAH rates and those publishing psychosocial research. Specifically, increased rates of CAH are seen in non-Western countries/regions, whereas most psychosocial research arises out of Western Europe and the US. Due to cultural differences between these regions, increased global collaboration is needed to both inform psychosocial research and translate findings in ways that are representative worldwide.
DOI: 10.6084/m9.figshare.23310830
title: Supplementary Material for: Paraneoplastic autoimmune limbic encephalitis associated with an atypical carcinoid tumor of the lung

description: We report the case of a patient with a history of an atypical lung carcinoid tumor who developed a rapidly progressive memory impairment. The clinical presentation as well as brain MRI, cerebrospinal fluid and laboratory tests led to the diagnosis of seronegative paraneoplastic autoimmune limbic encephalitis. To the best of our knowledge, this is the first case in literature of such association. This case also highlights an exceptionally favorable outcome, both clinically and radiologically, after immunosuppression and tumor removal.
DOI: 10.6084/m9.figshare.23310830.v1
title: Supplementary Material for: Paraneoplastic autoimmune limbic encephalitis associated with an atypical carcinoid tumor of the lung

description: We report the case of a patient with a history of an atypical lung carcinoid tumor who developed a rapidly progressive memory impairment. The clinical presentation as well as brain MRI, cerebrospinal fluid and laboratory tests led to the diagnosis of seronegative paraneoplastic autoimmune limbic encephalitis. To the best of our knowledge, this is the first case in literature of such association. This case also highlights an exceptionally favorable outcome, both clinically and radiologically, after immunosuppression and tumor removal.
DOI: 10.6084/m9.figshare.23294822
title: Supplementary Material for: Can growth hormone lead to a faster recovery from Guillain-Barrée syndrome? Case report of the first therapeutic use in one patient

description: Although the prognosis in Guillain-Barré syndrome (GBS) is generally good, protracted and incomplete courses of recovery can be a heavy burden. Animal studies suggest growth hormone (GH) treatment could stimulate myelin repair and thus accelerate functional recovery in acute polyneuropathy. We report on the first use of GH in GBS. Our objective was to monitor safety and tolerability as well as to evaluate the effect of an off-label GH therapy during recovery from GBS in one patient. A 28-year-old male with flaccid tetraparesis caused by pure motor GBS was treated off-label with GH (1 mg/day) for 10 weeks. Muscle strength was measured regularly before, during and after the treatment over a total span of 330d. Serum levels of IGF-I were assessed before, during and after GH treatment. Changes in strength gain were used as the main parameter of efficacy. No side effects of GH treatment were observed. Serum IGF-I increased from 177 ng/mL at baseline to an average of 342 ng/mL (normal range 78 – 270 ng/mL) during treatment. Prior to GH administration, strength (R²=0.99, p&lt;0.01) was associated with time, representing the natural course of recovery. During GH treatment, the slope of strength gain increased (Glass’ ∆=1.08, p&lt;0.01). The association between alterations of strength gain and IGF-I serum levels reached trend-level (R²=0.36, p=0.09). In this single case, GH treatment seemed to be associated with faster muscular strength gain. Controlled studies are needed in order to establish GH as a potential therapeutic approach in motor GBS.
DOI: 10.6084/m9.figshare.23294822.v1
title: Supplementary Material for: Can growth hormone lead to a faster recovery from Guillain-Barrée syndrome? Case report of the first therapeutic use in one patient

description: Although the prognosis in Guillain-Barré syndrome (GBS) is generally good, protracted and incomplete courses of recovery can be a heavy burden. Animal studies suggest growth hormone (GH) treatment could stimulate myelin repair and thus accelerate functional recovery in acute polyneuropathy. We report on the first use of GH in GBS. Our objective was to monitor safety and tolerability as well as to evaluate the effect of an off-label GH therapy during recovery from GBS in one patient. A 28-year-old male with flaccid tetraparesis caused by pure motor GBS was treated off-label with GH (1 mg/day) for 10 weeks. Muscle strength was measured regularly before, during and after the treatment over a total span of 330d. Serum levels of IGF-I were assessed before, during and after GH treatment. Changes in strength gain were used as the main parameter of efficacy. No side effects of GH treatment were observed. Serum IGF-I increased from 177 ng/mL at baseline to an average of 342 ng/mL (normal range 78 – 270 ng/mL) during treatment. Prior to GH administration, strength (R²=0.99, p&lt;0.01) was associated with time, representing the natural course of recovery. During GH treatment, the slope of strength gain increased (Glass’ ∆=1.08, p&lt;0.01). The association between alterations of strength gain and IGF-I serum levels reached trend-level (R²=0.36, p=0.09). In this single case, GH treatment seemed to be associated with faster muscular strength gain. Controlled studies are needed in order to establish GH as a potential therapeutic approach in motor GBS.
DOI: 10.6084/m9.figshare.23254787
title: Supplementary Material for: Efficacy of lipophilic statins on outcomes of patients treated with immune checkpoint inhibitors

description: Statins are associated with improved survival outcomes in patients receiving immune checkpoint inhibitors (ICIs), but the impact of different statins on outcomes is unknown. We conducted a retrospective cohort study to investigate if statins with lipophilic properties are associated with improved clinical outcomes in patients treated with ICIs. There were 51 lipophilic statin users, 25 hydrophilic statin users, and 658 non-users. Lipophilic statin users had a longer median OS (38.0 [IQR, 16.7-not reached] vs. 15.2 [IQR, 8.2–not reached] months vs. 18.9 [IQR, 5.4-51.6] months) and PFS (13.0 [IQR, 4.7–41.5] vs. 8.2 [IQR, 2.2–14.7] months vs. 5.6 [2.3-18.7] months) than hydrophilic statin users and non-statin users. In Cox proportional hazard analyses, the use of lipophilic statins was associated with a 40-50% lower risk of mortality and disease progression compared with hydrophilic statin or non-statin users. In conclusion, the use of lipophilic statins seems to be associated with survival benefits in patients undergoing immunotherapy.
DOI: 10.5517/ccdc.csd.cc1pk40d
title: CCDC 1565593: Experimental Crystal Structure Determination

description: Related Article: Fei Yu, Jing Li, Zi-Heng Cao, Mohamedally Kurmoo, Jing-Lin Zuo|2018|Inorg.Chem.|57|3443|doi:10.1021/acs.inorgchem.8b00243
description: An entry from the Cambridge Structural Database, the world’s repository for small molecule crystal structures. The entry contains experimental data from a crystal diffraction study. The deposited dataset for this entry is freely available from the CCDC and typically includes 3D coordinates, cell parameters, space group, experimental conditions and quality measures.
DOI: 10.5281/zenodo.8054554
title: ggCaller Supplemental Code

description: Datasets, analysis scripts and source code used in the ggCaller manuscript.
DOI: 10.5281/zenodo.8054555
title: ggCaller Supplemental Data S1

description: Datasets, analysis scripts and source code used in the ggCaller manuscript.
DOI: 10.5281/zenodo.8225171
title: ggCaller Supplemental Code

description: Datasets, analysis scripts and source code used in the ggCaller manuscript.
DOI: 10.6084/m9.figshare.23268470.v1
title: Supplementary Material for: A Phase 3b Study for Management of Ocular Side Effects in Patients with EGFR-Amplified Glioblastoma Receiving Depatuxizumab Mafodotin

description: Introduction: The Understanding New Interventions with GBM ThErapy (UNITE) study was designed to assess the effect of prophylaxis for ocular side effects (OSEs) in patients with glioblastoma receiving the antibody-drug conjugate (ADC) depatuxizumab mafodotin. UNITE (NCT03419403) was a phase 3b, open-label, randomized, exploratory study performed at 18 research sites in 5 countries. Methods: The study enrolled adult patients with epidermal growth factor receptor–amplified, histologically confirmed, newly diagnosed supra-tentorial glioblastoma or Grade IV gliosarcoma, and a Karnofsky Performance Status ≥70, receiving depatuxizumab mafodotin. All patients were administered depatuxizumab mafodotin during concurrent radiotherapy and temozolomide and with adjuvant temozolomide. Ninety patients were to be randomized (1:1:1) to OSE prophylactic treatments with each depatuxizumab mafodotin infusion: a) standard steroid eye drops, b) standard steroid eye drops plus vasoconstrictor eye drops and cold compress, or c) enhanced steroids plus vasoconstrictor eye drops and cold compress. A Corneal Epitheliopathy Adverse Event (CEAE) scale was devised to capture symptoms, grade OSEs (scale of 0–5), and inform ADC dose modifications. The primary endpoint was the frequency of a required change in OSE management due to inadequate control of OSEs, defined as decline from baseline in visual acuity (using logarithm of the minimum angle of resolution [LogMAR] scale) or a Grade ≥3 CEAE event, in the worst eye in the first 8 weeks of treatment; unless otherwise specified, the treatment period refers to both the chemoradiation and adjuvant phases. Results: The UNITE study was stopped early after interim analysis of separate phase III trial showed no difference in survival from depatuxizumab mafodotin. Forty patients were randomized (38 received depatuxizumab mafodotin). Overall, 23 patients experienced inadequate control of OSEs that required change in OSE management within 8 weeks of treatment, with 21 (70.0%) experiencing ≥+0.3 change on LogMAR scale in baseline-adjusted visual acuity and 12 reporting a Grade ≥3 CEAE. There were no definitive differences among prophylactic treatments. Conclusions: The premature cessation of the study precludes definitive conclusions regarding the OSE prophylaxis strategies. No new clinically significant safety findings were noted. Despite these limitations, this study highlights the need for novel assessment tools to better understand and mitigate OSEs associated with ADCs.
DOI: 10.6084/m9.figshare.23617203
title: Supplementary Material for: Smokers with Elevated Glycated Albumin Could Not Benefit from Dual Antiplatelet Therapy after Minor Stroke or Transient Ischemic Attack

description: <b><i>Introduction:</i></b> The aim of this study was to investigate the impact of smoking on dual antiplatelet therapy in patients with minor stroke or transient ischemic attack (TIA) under different glycated albumin (GA) levels. <b><i>Methods:</i></b> We analyzed data from the Clopidogrel in High-Risk Patients with Acute Nondisabling Cerebrovascular Events (CHANCE) trial. A subgroup of 3,044 patients with baseline GA levels was included and categorized by smoking status and GA levels. The primary efficacy outcome was a new stroke within 90 days. The safety outcome was any bleeding event at 90 days. The interaction of smoking status with antiplatelet therapy was calculated by Cox proportional hazards regression model. <b><i>Results:</i></b> In patients with GA levels ≤15.5%, the proportion of smokers was 37.7% (719/1,908), while in patients with GA levels &gt;15.5%, it was 51.6% (586/1,136). During the 3-month follow-up period, 299 (9.9%) patients had a new stroke occurrence. In patients with elevated GA levels, both smokers and nonsmokers could not benefit from dual antiplatelet therapy (smokers, adjusted hazard ratio [HR] 0.70, 95% confidence interval [CI]: 0.42–1.17; nonsmokers, adjusted HR 0.82, 95% CI: 0.57–1.18). In patients with normal GA levels, dual antiplatelet therapy reduced the risk of stroke recurrence in smokers by 72% (adjusted HR 0.28, 95% CI: 0.14–0.56) and in nonsmokers by 53% (adjusted HR 0.47, 95% CI: 0.26–0.86). However, whether the GA level was elevated or normal, there was no significant interaction between smoking status and antiplatelet therapy. <b><i>Conclusions:</i></b> Smokers with elevated GA levels could not benefit from dual antiplatelet therapy after minor stroke or TIA.
DOI: 10.6084/m9.figshare.23617203.v1
title: Supplementary Material for: Smokers with Elevated Glycated Albumin Could Not Benefit from Dual Antiplatelet Therapy after Minor Stroke or Transient Ischemic Attack

description: <b><i>Introduction:</i></b> The aim of this study was to investigate the impact of smoking on dual antiplatelet therapy in patients with minor stroke or transient ischemic attack (TIA) under different glycated albumin (GA) levels. <b><i>Methods:</i></b> We analyzed data from the Clopidogrel in High-Risk Patients with Acute Nondisabling Cerebrovascular Events (CHANCE) trial. A subgroup of 3,044 patients with baseline GA levels was included and categorized by smoking status and GA levels. The primary efficacy outcome was a new stroke within 90 days. The safety outcome was any bleeding event at 90 days. The interaction of smoking status with antiplatelet therapy was calculated by Cox proportional hazards regression model. <b><i>Results:</i></b> In patients with GA levels ≤15.5%, the proportion of smokers was 37.7% (719/1,908), while in patients with GA levels &gt;15.5%, it was 51.6% (586/1,136). During the 3-month follow-up period, 299 (9.9%) patients had a new stroke occurrence. In patients with elevated GA levels, both smokers and nonsmokers could not benefit from dual antiplatelet therapy (smokers, adjusted hazard ratio [HR] 0.70, 95% confidence interval [CI]: 0.42–1.17; nonsmokers, adjusted HR 0.82, 95% CI: 0.57–1.18). In patients with normal GA levels, dual antiplatelet therapy reduced the risk of stroke recurrence in smokers by 72% (adjusted HR 0.28, 95% CI: 0.14–0.56) and in nonsmokers by 53% (adjusted HR 0.47, 95% CI: 0.26–0.86). However, whether the GA level was elevated or normal, there was no significant interaction between smoking status and antiplatelet therapy. <b><i>Conclusions:</i></b> Smokers with elevated GA levels could not benefit from dual antiplatelet therapy after minor stroke or TIA.